Journal article · 2021 · Open access
Alzheimer's disease drug development pipeline: 2021
Alzheimer s & Dementia Translational Research & Clinical Interventions, 7(1), e12179 · Published 1 January 2021 · DOI 10.1002/trc2.12179
In brief
“Alzheimer's disease drug development pipeline: 2021” is a 2021 journal article by Jeffrey L. Cummings and 4 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 589 citations as of 15 November 2026, which puts it in the top 5% of works published in 2021 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.
- Citations
- 589
- Most cited in
- 2022 (162)
- Field-weighted impact
- 37.07
- References
- 38
- Authors
- 5
Abstract
INTRODUCTION: The number of individuals worldwide with Alzheimer's disease (AD) is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs in clinical trials for the treatment of AD. METHODS: We interrogated ClinicalTrials.gov, the federal registry of clinical trials to identify drugs in trials. RESULTS: There are 126 agents in 152 trials assessing new therapies for AD: 28 treatments in Phase 3 trials, 74 in Phase 2, and 24 in Phase 1. The majority of drugs in trials (82.5%) target the underlying biology of AD with the intent of disease modification; 10.3% are putative cognitive enhancing agents; and 7.1% are drugs being developed to reduce neuropsychiatric symptoms. DISCUSSION: This pipeline analysis shows that target biological processes are more diversified, biomarkers are more regularly used, and repurposed agents are being explored to determine their utility for the treatment of AD.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Cummings, J. L., Lee, G., Zhong, K., Cacho, J. R. F., & Taghva, K. (2021). Alzheimer's disease drug development pipeline: 2021. Alzheimer s & Dementia Translational Research & Clinical Interventions, 7(1), e12179. https://doi.org/10.1002/trc2.12179
MLA 9
Cummings, Jeffrey L., et al. “Alzheimer's disease drug development pipeline: 2021.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 7, no. 1, 2021, p. e12179. https://doi.org/10.1002/trc2.12179.
Chicago
Cummings, Jeffrey L., Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, and Kazem Taghva. 2021. “Alzheimer's disease drug development pipeline: 2021.” Alzheimer s & Dementia Translational Research & Clinical Interventions 7 (1): e12179. https://doi.org/10.1002/trc2.12179.
Harvard
Cummings, J. L. et al. (2021) ‘Alzheimer's disease drug development pipeline: 2021’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 7(1), p. e12179. doi:10.1002/trc2.12179.
IEEE
J. L. Cummings, G. Lee, K. Zhong, J. R. F. Cacho, and K. Taghva, “Alzheimer's disease drug development pipeline: 2021,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 7, no. 1, p. e12179, 2021, doi: 10.1002/trc2.12179.
BibTeX
@article{cummings2021alzheimer,
title = {{Alzheimer's disease drug development pipeline: 2021}},
author = {Cummings, Jeffrey L. and Lee, Garam and Zhong, Kate and Cacho, Jorge Ramón Fonseca and Taghva, Kazem},
journal = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
year = {2021},
volume = {7},
number = {1},
pages = {e12179},
doi = {10.1002/trc2.12179},
url = {https://doi.org/10.1002/trc2.12179}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2020 | 3 | |
| 2021 | 53 | |
| 2022 | 162 | |
| 2023 | 107 | |
| 2024 | 90 | |
| 2025 | 112 | |
| 2026 | 62 |
Its field-weighted citation impact is 37.07: it has been cited 37.07 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- drug development pipeline
- clinical trials
- disease-modifying therapy
- cognitive enhancement
- neuropsychiatric symptoms
- drug repurposing
- biomarkers
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Cummings, J. L., Lee, G., Zhong, K., Cacho, J. R. F., & Taghva, K. (2021). Alzheimer's disease drug development pipeline: 2021. Alzheimer s & Dementia Translational Research & Clinical Interventions, 7(1), e12179. https://doi.org/10.1002/trc2.12179
How many times has this paper been cited?
589 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.
Who wrote this paper?
Jeffrey L. Cummings, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, Kazem Taghva.
What is the DOI of this paper?
10.1002/trc2.12179. The permanent link is https://doi.org/10.1002/trc2.12179.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.